Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan Dual Therapy vs Furazolidone-based Bismuth Quadruple Therapy for H. Pylori Eradication
NCT06340334Completed
- Sponsor
- Nanjing First Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tegoprazan in Helicobacter pylori infection (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Helicobacter pylori eradication rate. Started Mar 2024; status: completed.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06340334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340334.